BI wants to 'own' lung therapy space as India-priced afatinib debuts
This article was originally published in Scrip
Executive Summary
"We want to own the lung cancer therapy space," is how Boehringer Ingelheim (BI) India's managing director Sharad Tyagi refers to the family-owned German multinational's ambitions in the segment with the introduction of its first oncology product, afatinib, on the domestic market.